middle.news
Actinogen Medical Nets $5.5m R&D Rebate, Fuels Alzheimer’s Trial Momentum
9:02am on Wednesday 15th of October, 2025 AEDT
•
Healthcare
Read Story
Actinogen Medical Nets $5.5m R&D Rebate, Fuels Alzheimer’s Trial Momentum
9:02am on Wednesday 15th of October, 2025 AEDT
Key Points
Received $5.49 million R&D tax rebate for FY2025
Additional $1.87 million rebate pending ATO approval
Repaid $3 million loan advanced against rebate
Supports ongoing XanaMIA Phase 2b/3 Alzheimer’s trial
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Actinogen Medical (ASX:ACW)
OPEN ARTICLE